Internet meme

MeMed Further Solidifies Board of Directors Appointing Scott Garrett

Retrieved on: 
Thursday, November 9, 2023
Water, MA, AdvaMed, Dade Behring, Health, Senior, Internet meme, Growth, Baxter International, Water Street, Minerva Surgical, Inc. v. Hologic, Inc., Beckman Coulter, Management

HAIFA, Israel; BOSTON, MA – 9 November, 2023 – MeMed, a leader in host response technologies, today announces the appointment of Scott Garrett to its Board of Directors.

Key Points: 
  • HAIFA, Israel; BOSTON, MA – 9 November, 2023 – MeMed, a leader in host response technologies, today announces the appointment of Scott Garrett to its Board of Directors.
  • Scott Garrett is currently a Senior Operating Partner at Water Street Healthcare Partners, a private equity firm focused solely on healthcare investments.
  • I'm truly enthusiastic about my appointment to MeMed's Board of Directors and eagerly anticipate helping the MeMed team achieve its operational and strategic goals.”
    Dr. Eran Eden, CEO of MeMed, noted, “We’re excited to welcome Scott Garrett to our Board and leadership team.
  • I look forward to working with Scott to further our mission and establish MeMed as a leader in the emerging field of advanced host-response.”

MeMed: FDA Clears Pioneering MeMed BV Test Direct From Whole Blood Allowing Faster Time To Result And Broader Patient Access When Distinguishing Bacterial From Viral Infections

Retrieved on: 
Wednesday, July 19, 2023
Maintenance, Serum, Point, Risk, Viral, Hospital, FDA, Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Internet meme, Vaccine

Through newly developed technology, MeMed BV on whole blood can accurately and quickly measure multiple proteins present in low concentrations from a small volume of whole blood.

Key Points: 
  • Through newly developed technology, MeMed BV on whole blood can accurately and quickly measure multiple proteins present in low concentrations from a small volume of whole blood.
  • Eran Eden, CEO of MeMed: “The FDA clearance of MeMed BV on whole blood is a significant milestone in our journey to make bacterial versus viral infection testing a standard of care.
  • The basis of physician prescription of unnecessary antibiotics is diagnostic uncertainty – is the patient presenting with a bacterial or a viral infection?
  • I anticipate that this will enhance both patient and physician satisfaction.”

MeMed: FDA Clears Pioneering MeMed BV Test Direct From Whole Blood Allowing Faster Time To Result And Broader Patient Access When Distinguishing Bacterial From Viral Infections

Retrieved on: 
Wednesday, July 19, 2023
Maintenance, Serum, Point, Risk, Viral, Hospital, FDA, Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Internet meme, Vaccine

Through newly developed technology, MeMed BV on whole blood can accurately and quickly measure multiple proteins present in low concentrations from a small volume of whole blood.

Key Points: 
  • Through newly developed technology, MeMed BV on whole blood can accurately and quickly measure multiple proteins present in low concentrations from a small volume of whole blood.
  • Eran Eden, CEO of MeMed: “The FDA clearance of MeMed BV on whole blood is a significant milestone in our journey to make bacterial versus viral infection testing a standard of care.
  • The basis of physician prescription of unnecessary antibiotics is diagnostic uncertainty – is the patient presenting with a bacterial or a viral infection?
  • I anticipate that this will enhance both patient and physician satisfaction.”

MeMed: Nutex Health Announces Agreement with MeMed to Adopt Pioneering MeMed BV® Test Across its Network of 19 sites

Retrieved on: 
Thursday, May 25, 2023
Partnership, Hospital, Patient, Physician, Machine learning, Immune system, Nutex Health, Infection, Growth, Genetically modified bacteria, FDA, Internet meme, Vaccine, Pharmaceutical industry

The test distinguishes viral from bacterial infections in 15 minutes and applies machine learning to translate the complex signaling of the immune system into simple, actionable diagnostic insights.

Key Points: 
  • The test distinguishes viral from bacterial infections in 15 minutes and applies machine learning to translate the complex signaling of the immune system into simple, actionable diagnostic insights.
  • The agreement follows successful agreements between MeMed and Nutex Health hospitals Tucson ER & Hospital and Tulsa ER & Hospital, demonstrating the value this technology brings to the emergency room.
  • Nutex Health is comprised of 19 state-of-the-art micro hospitals in eight states and a primary care-centric risk bearing physician network.
  • Michael Chang, M.D., Nutex Health Chief Medical Officer, said, “Nutex Health’s mission is to provide accessible and exceptional concierge-level healthcare to patients throughout the markets we serve.

Beckman Coulter and MeMed to Expand Access to Proven Host Immune Response Diagnostic Able to Distinguish Between Bacterial and Viral Infections

Retrieved on: 
Tuesday, January 31, 2023
Emergency medicine, Viral, Death, Microbiology, Internet meme, Genetically modified bacteria, MDW, Machine learning, Partnership, US, US FDA, Ministry, Public, Physician, Infection, CRP, TRAIL, Standstill, Patient, Ambiguity, Vaccine, Pharmaceutical industry, Health

BREA, Calif. and HAIFA, Israel, Jan. 31, 2023 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in clinical diagnostics, and MeMed, a leader in the emerging field of advanced host-response technologies, announced today a strategic partnership to jointly develop and commercialize the proven MeMed BV® test, a host immune response diagnostic that is able to distinguish between bacterial and viral infections for use on the Access Family of Immunoassay Analyzers.

Key Points: 
  • Symptoms of bacterial and viral infections are often clinically indistinguishable, which creates challenges for physicians when deciding to start treating patients with antibiotics or not.
  • The MeMed BV test uses machine learning to integrate measurements of three key host-immune proteins (TRAIL, IP-10, and CRP) into a score indicating the likelihood of bacterial or viral infections.
  • MeMed BV on MeMed Key is US FDA cleared, CE-Marked and approved by the Israeli Ministry of Health.
  • The ability to distinguish between bacterial and viral infections early in the diagnostic process has significant potential to impact patient care, as well as combat antimicrobial resistance," said Julie Sawyer Montgomery, President, Beckman Coulter.

Tulsa ER & Hospital Adopts Trailblazing MeMed BV® Test

Retrieved on: 
Thursday, December 22, 2022
Communication, Infection, Internet meme, Serum, Urinary tract infection, Emergency, Genetically modified bacteria, Patient, Degenerative disease, Physician, Machine learning, FDA, Immune system, Diagnosis, Hospital, Pharmaceutical industry

HAIFA, Israel and TULSA, Oklahoma, December 22, 2022 – MeMed, a leader in the emerging field of advanced host-response technologies, and Tulsa ER & Hospital, a physician-managed facility with a mission to restore the provider and patient relationship through communication and individualized treatment plans, today announce that Tulsa ER & Hospital is adopting the trailblazing MeMed BV® test that distinguishes between a bacterial and viral infection in just 15 minutes from serum.

Key Points: 
  • HAIFA, Israel and TULSA, Oklahoma, December 22, 2022 – MeMed, a leader in the emerging field of advanced host-response technologies, and Tulsa ER & Hospital, a physician-managed facility with a mission to restore the provider and patient relationship through communication and individualized treatment plans, today announce that Tulsa ER & Hospital is adopting the trailblazing MeMed BV® test that distinguishes between a bacterial and viral infection in just 15 minutes from serum.
  • MeMed’s technology applies machine learning to translate the complex signaling of the immune system into simple, actionable diagnostic insights.
  • The MeMed BV test aids physicians to enhance patient management and make more informed antibiotic treatment decisions.
  • Dr. Mark Blubaugh, Chief Medical Officer & ER Physician, Tulsa ER & Hospital said, “We at Tulsa ER & Hospital are excited to offer the new MeMed BV test.

Tucson ER & Hospital Adopts Trailblazing MeMed BV® Test

Retrieved on: 
Tuesday, October 25, 2022
Population Health Management, Physician, Communication, Hospital, Machine learning, Infection, Genetically modified bacteria, NASDAQ, Patient, MRI, Technology, Immune system, CEO, Emergency, Internet meme, Injury, FDA, Pharmaceutical industry, Medical imaging

Tucson ER & Hospital is the first community-based, stand-alone ER and Hospital facility to adopt the FDA-approved technology that distinguishes viral from bacterial infection in 15 minutes

Key Points: 
  • Tucson ER & Hospital is the first community-based, stand-alone ER and Hospital facility to adopt the FDA-approved technology that distinguishes viral from bacterial infection in 15 minutes
    HAIFA, Israel and TUCSON, Arizona, October 25, 2022 MeMed, a leader in the emerging field of advanced host-response technologies, and Tucson ER & Hospital, a physician-managed facility with a mission to restore the provider and patient relationship through communication and individualized treatment plans, today announce that Tucson is adopting the trailblazing MeMed BV test that distinguishes viral from bacterial infection within 15 minutes.
  • Dr. Darren Kay, Chief Operating Officer & ER Physician, Tucson ER & Hospital said, We at Tucson ER & Hospital are proud to announce the latest addition to our in-house laboratory technology, the MeMed BV test.
  • Tucson ER & Hospital is an accredited, 24/7, full-service hospital and emergency department that is set to celebrate three years of service to the Tucson community in October.
  • The Hospital division currently owns and operates 21 health care facilities in eight different states, including Tucson ER & Hospital.

Lifestyle and Apparel Brand, RSVLTS, Brings Home Coveted The Pop Insider Holiday Gift Guide Recognition for its Spider-Man "The Meme" Kunuflex™ Shirt

Retrieved on: 
Tuesday, October 18, 2022
Roosevelt family, Pop, Editorial, Multimedia, Collection, Marvel, Clothing, New York Comic Con, Social media, Television, Internet meme, Communication, Meme, Cartoon, Nightclub, Entertainment, Fashion, Spider-Man

HOBOKEN, N.J., Oct. 18, 2022 /PRNewswire/ -- Today, RSVLTS (Roosevelts), creators of high-quality licensed and unlicensed apparel since 2012, are thrilled to once again announce its inclusion within the The Pop Insider 2022 Holiday Gift Guide for a very special button-down that was launched earlier this year: Spider-Man "The Meme."

Key Points: 
  • Selected from thousands of fandom-based gift entries, the item falls within the publication's apparel category, awarded as Best Geeky Gift ("The Meme") .
  • The Pop Insider 2022 Holiday Gift Guide, which went live online and via social media on October 6, showcases editorial picks for the top holiday gift items released within that year, also distributed via a print version at the the renowned New York Comic Con earlier in October.
  • "We love that RSVLTS' apparel is super fashionable and stylish and upon a closer look, packed with details that fans will love," said Ali Mierzejewski, Editor-in-Chief of The Pop Insider.
  • "RSVLTS' Spider-Man 'The Meme' shirt features the iconic meme of the pointing hero that will delight both fans of the web-slinger and those who love getting lost in the interwebs."

Dr. Sergey Motov at Maimonides Medical Center to Host Webinar on using MeMed BV® in the Emergency Department to rapidly differentiate bacterial and viral infections

Retrieved on: 
Wednesday, July 13, 2022
Emergency, Hospital, SUNY Downstate College of Medicine, Maimonides, Solution, IDT, Maimonides Medical Center, Patient, Emergency department, Physician, Education, Northwell Health, Internet meme, Yale Cancer Center, Medical Center, Department, Research, Serum, Emergency medicine, Vaccine

From research to clinical use of MeMed BV in the Emergency Department where he will share how he and his team use the MeMed BV test in the Emergency Department to rapidly differentiate between bacterial and viral infections.

Key Points: 
  • From research to clinical use of MeMed BV in the Emergency Department where he will share how he and his team use the MeMed BV test in the Emergency Department to rapidly differentiate between bacterial and viral infections.
  • The webinar will take place on July 21, 2022 at 1:00 pm EDT/ 7:00 pm CET/ 8:00 pm IDT.
  • Dr. Motov will describe MeMed BV, a first-of-its kind test that decodes the immune response and accurately differentiates between bacterial or viral infections in 15 minutes from serum.
  • Dr. Motov will also discuss patient selection, clinical implementation, and the initial impact of using MeMed BV in his Emergency Department.

Maccabi Healthcare Services announces it is the first HMO in the world to include MeMed BV® test as part of routine care

Retrieved on: 
Tuesday, June 7, 2022
Health maintenance organization, Infection, Time, Food, CEO, Public, News, Partnership, Defense, CE marking, Physician, Ministry, CRP, FDA, Patient, Maccabi Healthcare Services, Risk, Technology, Food and Drug Administration, European Commission, Diagnosis, Genetically modified bacteria, Medicine, Internet meme, Protein, Medical device, Pharmaceutical industry, Vaccine, Maccabi, Health

Maccabi is one of the largest health maintenance organizations (HMOs) in the world, with 2.5 million members and about 100,000 medical interactions per day.

Key Points: 
  • Maccabi is one of the largest health maintenance organizations (HMOs) in the world, with 2.5 million members and about 100,000 medical interactions per day.
  • Maccabi Healthcare Services will make the technology available in all the organizations urgent care centers starting this month.
  • Maccabi Healthcare Services is one of the world's largest public healthcare providers with 2.5 million members.
  • The MeMed Key development program has been partially funded by the US Department of Defense and the EU Commission.